U.S. markets closed

Catalent, Inc. (CTLT)

NYSE - NYSE Precio retrasado. Divisa en USD.
Añadir a la lista de seguimiento
55.48-0.32 (-0.57%)
Al cierre: 04:00PM EDT
55.37 -0.11 (-0.20%)
Fuera de horario: 07:10PM EDT

Catalent, Inc.

14 Schoolhouse Road
Somerset, NJ 08873
United States
732 537 6200
https://www.catalent.com

Sector(es)Healthcare
IndustriaDrug Manufacturers - Specialty & Generic
Empleados a tiempo completo18,000

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Alessandro MaselliPresident, CEO & Director1.08MN/D1972
Dr. Aristippos Gennadios Ph.D.Group President of Pharma & Consumer Health Segment799.26kN/D1966
Mr. Ricky HopsonPresident, Division Head for BioProduct Delivery & Chief of Staff622.12kN/D1977
Mr. John J. Greisch M.B.A.Executive Chairman of the Board125kN/D1955
Mr. Matti M. MasanovichSenior VP & CFON/DN/D1972
Mr. Charles LickfoldSenior VP & Chief Information OfficerN/DN/D1974
Mr. Paul SurdezVice President of Investor RelationsN/DN/DN/D
Mr. Michael J. GrippoSenior Vice President of Strategy & Corporate DevelopmentN/DN/D1969
Ms. Lisa EvoliSenior VP & Chief Human Resources OfficerN/DN/D1970
Mr. Scott GuntherSenior Vice President of Quality & Regulatory AffairsN/DN/D1967
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

Gestión corporativa

La calificación ISS Governance QuickScore de Catalent, Inc. a partir del 1 de abril de 2024 es 10. Las puntuaciones principales son Auditoría: 10; Junta: 8; Derechos del accionista: 7; Compensación: 7.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.